State Street SPDR S&P Biotech ETF
431 hedge funds and large institutions have $5.76B invested in State Street SPDR S&P Biotech ETF in 2018 Q2 according to their latest regulatory filings, with 64 funds opening new positions, 153 increasing their positions, 123 reducing their positions, and 43 closing their positions.
49% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 43
24% more repeat investments, than reductions
Existing positions increased: 153 | Existing positions reduced: 123
16% more funds holding in top 10
Funds holding in top 10: 19 → 22 (+3)
12% more capital invested
Capital invested by funds: $5.13B → $5.76B (+$635M)
4.89% more ownership
Funds ownership: 106.36% → 111.25% (+4.9%)
4% more funds holding
Funds holding: 414 → 431 (+17)
28% less call options, than puts
Call options by funds: $1.36B | Put options by funds: $1.9B
Top Buyers
| 1 |
UBS Group
Zurich,
Switzerland
|
+$188M |
| 2 |
Morgan Stanley
New York
|
+$169M |
| 3 |
AssetMark Inc
Concord,
California
|
+$116M |
| 4 |
Goldman Sachs
New York
|
+$94.8M |
| 5 |
SG Americas Securities
New York
|
+$55.2M |
Top Sellers
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$185M |
| 2 |
Rafferty Asset Management
New York
|
-$98.8M |
| 3 |
Citigroup
New York
|
-$75.4M |
| 4 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$69.1M |
| 5 |
NM
NWI Management
New York
|
-$52.6M |
XBI Hedge Fund Activity: Q2 2018 in Review
431 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2018, worth a combined $5.76B — up 12% from $5.13B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new XBI positions and 43 closed out — a net gain of 21 holders — while 153 added to existing stakes and 123 trimmed.
The largest buyer was UBS Group, adding an estimated $188M. The largest seller was Deutsche Bank, cutting an estimated $185M.
- 431 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2018, up from 414 in Q1 2018.
- Funds reported $5.76B of State Street SPDR S&P Biotech ETF stock for Q2 2018, up 12% quarter-over-quarter.
- 64 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2018 and 43 closed out, a net change of +21 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2018 was UBS Group, an estimated $188M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2018 was Deutsche Bank, an estimated $185M sold.
Based on aggregated 13F filings for Q2 2018.